Chemical inhibitors of cyclin-dependent kinases insights into design from X-ray crystallographic studies

Pharmacology and Therapeutics

Volumn 82, Issue 2-3, 1999, Pages 269-278

  Noble, Martin E M ^a   Endicott, Jane A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

CDK, cyclin dependent kinase; Cell cycle; Cyclin dependent kinases; Drug design; Protein phosphorylation; Small molecule inhibitors; X ray crystallography

Indexed keywords

5 HYDROXYMETHYL 2 PYRROLIDINOGUANINE; 6 O CYCLOHEXYLMETHYLGUANINE; ADENOSINE TRIPHOSPHATE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; L 868276; PURVALANOL; RIBOSE PHOSPHATE; ROSCOVITINE; STAUROSPORINE; UNCLASSIFIED DRUG;

BINDING SITE; CANCER; CELL CYCLE; CELL PROLIFERATION; CONFERENCE PAPER; CRYSTAL STRUCTURE; DRUG DESIGN; ENZYME ACTIVE SITE; PRIORITY JOURNAL; PROTEIN FAMILY; REGULATORY MECHANISM; X RAY CRYSTALLOGRAPHY;

ADENOSINE TRIPHOSPHATE; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; CYCLINS; DRUG DESIGN; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; MOLECULAR STRUCTURE; PHOSPHOTRANSFERASES; SENSITIVITY AND SPECIFICITY;

EID: 0033028071     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(98)00051-5     Document Type: Conference Paper

References (45)

1. Brooks E.E., Gray N.S., Joly A., Kerwar S.S., Lum R., Mackman R.L., Norman T.C., Rosete J., Rowe M., Schow S.R., Schultz P.G., Wang X., Wick M.M., Shiffman D. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J. Biol. Chem. 272:1997;29207-29211.
2. Brown N.R., Noble M.E.M., Endicott J.A., Garman E.F., Wakatsuki S., Mitchell E.P., Rasmussen B., Hunt T., Johnson L.N. The crystal structure of cyclin A. Structure. 3:1995;1235-1247.
3. Brown N.R., Noble M.E.M., Lawrie A.M., Morris M.C., Tunnah P., Divita G., Johnson L.N., Endicott J.A. Characterisation of monomeric CDK2 phosphorylated on Threonine 160. J. Biol. Chem. in press:1999.
4. Connolly M. Molecular surface triangulation. J. Appl. Crystallogr. 18:1985;499-505.
5. Davis P.D., Hill C.H., Lawton G., Nixon J.S., Wilkinson S.E., Hurst S.A., Keech E., Turner S.E. Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J. Med. Chem. 35:1992;177-184.
6. De Azevedo W.F., Mueller-Dieckmann H.-J., Schulze-Gahmen U., Worland P.J., Sausville E., Kim S.-H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA. 93:1996;2735-2740.
7. De Azevedo W.F., Leclerc S., Meijer L., Havlicek L., Strnad M., Kim S.-H. Inhibition of cyclin-dependent kinases by purine analogues. Crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243:1997;518-526.
8. De Bondt H.L., Rosenblatt J., Jancarik J., Jones H.D., Morgan D.O., Kim S.-H. Crystal structure of cyclin-dependent kinase 2. Nature. 363:1993;595-602.
9. Draetta G.F. Will the real Cdk-activating kinase please stand up. Curr. Biol. 7:1997;R50-R52.
10. Elledge S.J. Cell cycle checkpoints. preventing an identity crisis Science. 274:1996;1664-1672.
11. Elledge S.J., Harper J.W. Cdk inhibitors. on the threshold of checkpoints and development Curr. Opin. Cell Biol. 6:1994;847-852.
12. Furet P., Caravatti G., Lydon N., Priestle J.P., Sowadski J.M., Trinks U., Traxler P. Modelling study of protein kinase inhibitors. binding mode of staurosporine and origin of the selectivity of CGP 52411 J. Comput. Aided Mol. Des. 9:1995;465-472.
13. Glab N., Labidi B., Qin L.-X., Trehin C., Bergounioux C., Meijer L. Olomoucine, an inhibitor of the cdc2/cdk2 kinase activities, blocks plant cells at the G1 to S and G2 to M cell cycle transitions. FEBS Lett. 353:1994;207-211.
14. Goodford P. Multivariate characterization of molecules for QSAR. J. Chemometrics. 10:1996;107-117.
15. Gray N.S., Wodicka L., Thunnissen A.M.W.H., Norman T.C., Kwon S., Espinoza F.H., Morgan D.O., Barnes G., Leclerc S., Meijer L., Kim S.-H., Lockhart D.J., Schultz P.G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 281:1998;533-538.
16. Hanks S.K., Hunter T. The eukaryotic protein kinase superfamily. kinase (catalytic) domain structure and classification FASEB J. 9:1995;576-596.
17. Hershko A. Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr. Opin. Cell Biol. 9:1997;788-799.
18. Jeffrey P.D., Russo A.A., Polyak K., Gibbs E., Hurwitz J., Massague J., Pavletich N.P. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature. 376:1995;313-320.
19. Johnson L.N., Noble M.E.M., Owen D.J. Active and inactive protein kinases. structural basis for regulation Cell. 85:1996;149-158.
20. Jones T.A., Zou J.Y., Cowan S.W., Kjeldgaard M. Improved method for building models in electron density maps and the location of errors in these models. Acta Crystallogr. A. 47:1991;110-119.
21. Kamb A. Cell-cycle regulators and cancer. Trends Genet. 11:1995;136-140.
22. Kase H., Iwahashi K., Nakanishi S., Matsuda Y., Yamada K., Takahashi M., Murakata C., Sato A., Kaneko M. K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem. Biophys. Res. Commun. 142:1987;436-440.
23. Kitagawa M., Okabe T., Ogino H., Matsumoto H., Suzuki-Takahashi I., Kokubo T., Higashi H., Saitoh S., Taya Y., Yasuda H., Ohba Y., Nishimura S., Tanaka N., Okuyama A. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene. 8:1993;2425-2432.
24. Lawrie A.M., Noble M.E.M., Tunnah P., Brown N.R., Johnson L.N., Endicott J.A. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nature Struct. Biol. 4:1997;796-801.
25. Legraverend M., Ludwig O., Bisagni E., Leclerc S., Meijer L. Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases. Bioorg. Med. Chem. Lett. 8:1998;793-798.
26. Meggio F., Donella-Deana A., Ruzzene M., Brunati A.M., Cesaro L., Guerra B., Meyer T., Mett H., Fabbro D., Furet P., Dobrowolska G., Pinna L.A. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur. J. Biochem. 234:1995;317-322.
27. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Meijer L., Guidet S., Tung H.Y.L. Progress in Cell Cycle Research, Vol. 1. 1995;351-363 Plenum Press, New York.
28. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol. 6:1996;393-397.
29. Meijer L., Kim S.-H. Chemical inhibitors of cyclin-dependent kinases. Methods Enzymol. 283:1997;113-128.
30. Meijer L., Borgne A., Mulner O., Chong J.P.J., Blow J.J., Inagaki N., Inagaki M., Delcros J.-G., Moulinoux J.-P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243:1997;527-536.
31. Morgan D.O. Cyclin-dependent kinases. engines, clocks and microprocessors Annu. Rev. Cell Dev. Biol. 13:1997;261-291.
32. Nakanishi S., Matsuda Y., Iwahashi K., Kase H. K-252b, c and d, potent inhibitors of protein kinase C from microbial origin. J. Antibiot. 39:1986;1066-1071.
33. Osada H., Takahashi H., Tsunoda K., Kusakabe H., Isono K. A new inhibitor of protein kinase C, RK-286C (4′-demethylamino-4′-hydroxystaurosporine). J. Antibiot. 43:1990;163-167.
34. Paulovich A.G., Toczyski D.P., Hartwell L.H. When checkpoints fail. Cell. 88:1997;315-321.
35. Pines J. Cyclins and cyclin-dependent kinases. a biochemical view Biochem. J. 308:1995;697-711.
36. Prade L., Engh R.A., Girod A., Kinzel V., Huber R., Bossemeyer D. Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. Structure. 5:1997;1627-1637.
37. Russo A., Jeffrey P.D., Pavletich N.P. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nature Struct. Biol. 3:1996;696-700.
38. Schulze-Gahmen U., Brandsen J., Jones H.D., Morgan D.O., Meijer L., Vesely J., Kim S.-H. Multiple modes of ligand recognition. crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine Proteins Struc. Funct. Genet. 22:1995;378-391.
39. Schulze-Gahmen U., DeBondt H.L., Kim S.-H. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP. bound waters and natural ligand as guides for inhibitor design J. Med. Chem. 39:1996;4540-4546.
40. Senderowicz A.M., Headlee D., Stinson S., Lush R.M., Tompkins A., Brawley O., Bergan R., Figg W.D., Smith A., Sausville E.A. Phase I trial of a novel cyclin-dependent kinase inhibitor flavopiridol in patients with refractory neoplasms. Ann. Oncol. 7(Suppl. 1):1996;77.
41. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
42. 1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
43. Toledo L.M., Lydon N.B. Structures of staurosporine bound to CDK2 and cAPK - new tools for structure-based design of protein kinase inhibitors. Structure. 5:1997;1551-1556.
44. Tong L., Pav S., White D.M., Rogers S., Crane K.M., Cywin C.L., Brown M.L., Pargellis C.A. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nature Struct. Biol. 4:1997;311-316.
45. Vesely J., Havlicek L., Strnad M., Blow J.J., Donella-Deana A., Pinna L., Letham D.S., Kato J.-Y., Detivaud L., Leclerc S., Meijer L. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 224:1994;771-786.